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In 1996, tamoxifen, a selective oestrogen receptor
modulator (SERM)-type drug and one of the most
successful and widely prescribed anti-neoplastic agents
worldwide, was classiﬁed by International Agency for
Research on Cancer-World Health Organisation
(IARC-WHO) as a ‘group-one’ human carcinogen [1].
Similar carcinogenic qualities are now emerging for
toremifene, a fellow SERM. The mechanistic basis for
tamoxifen carcinogenicity has been explored by nu-
merous researchers and has largely focused upon the
potential, as seen in experimental animals, for the drug
to be metabolised to genotoxic species that bind co-
valently to DNA and cause mutation. The presence of
such DNA adducts in human tissues and, most im-
portantly, in the target tissue, the endometrium, has
been the source of considerable debate. Initial studies,
seeking the presence of tamoxifen-DNA adducts in
patients treated with the drug and analysed by the 32P-
post-labelling technique, failed to ﬁnd any evidence of
genotoxic damage [2]. This was also supported by an
analysis of endometrial explant cultures treated with
tamoxifen and subsequent high performance liquid
chromatographic (HPLC) analysis of 32P-post-labelled
endometrial DNA from a further cohort of patients.
However, some subsequent studies have since suggested
that adducts may be detectable in the human endo-
metrium in women on tamoxifen therapy, although
inter-laboratory validation of these claims needs to be
performed [3]. Hence, the debate continues as to whe-
ther the drug is a genotoxic carcinogen in humans or
not. However, regardless of the presence or absence of
DNA adducts, tamoxifen is often responsible for rapid
and benign changes in endometrial pathology, such as
hyperplasia and polyps. This has been attributed to the
oestrogen agonist activity of tamoxifen in this tissue,
but rapid tamoxifen-speciﬁc induction of adenomyosis
in mice and endometrial tumours in neonatal rats in
the absence of oestrogenic hyperplasia, suggest that
tamoxifen has qualities beyond oestrogen agonist ac-
tivity [4] that may contribute to an epigenetic and non-
genotoxic mechanism of carcinogenicity. For example,
we have reported that tamoxifen can induce a mito-
genic environment in the human endometrium based
on dysregulation of transforming growth factor beta
and cognate receptors. To consider tamoxifen as an
adduct-forming genotoxin is an oversimpliﬁcation of
the carcinogenic proﬁle of this drug. A more complete
understanding of these processes is required to assist in
future SERM development and safety assessment. To
this end, we have sought to compare and characterise
the transcript proﬁle of tamoxifen, raloxifene and the
agonist oestradiol in human endometrial cells. Using
primary cultures of human endometria, to best emulate
the in vivo responses in a manageable in vitro system,
we have shown 230 signiﬁcant changes in gene ex-
pression for epithelial cultures and 83 in stromal cul-
tures, either speciﬁc to 17b-oestradiol, tamoxifen or
raloxifene, or changed across more than one of the
treatments. Considering the transcriptome as a whole,
the endometrial responses to raloxifene or tamoxifen
were more similar than either drug was to 17b-oestra-
diol. Treatment of endometrial cultures with tamoxifen
resulted in the largest number of gene changes relative
to control cultures and a high proportion of genes
associated with regulation of gene transcription, cell-
cycle control and signal transduction. Tamoxifen-spe-
ciﬁc changes that might point towards mechanisms for
its proliferative response in the endometrium included
changes in retinoblastoma and c-myc binding proteins,
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the APCL, DHFR and E2F1 genes and other tran-
scription factors. Tamoxifen was also found to give rise
to the highest number of gene expression changes
common to those that characterise malignant endo-
metria [5]. It is anticipated that this study will provide
leads for further and more focused investigation into
SERM carcinogenicity.
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